Yahoo
Shanghai - Delayed Quote CNY

Sichuan Hebang Biotechnology Corporation Limited (603077.SS)

2.0000 -0.0100 (-0.50%)
At close: October 30 at 3:00:02 PM GMT+8
Chart Range Bar
Loading chart for 603077.SS
  • Previous Close 2.0100
  • Open 2.0000
  • Bid 2.0000 x --
  • Ask 2.0100 x --
  • Day's Range 1.9700 - 2.0400
  • 52 Week Range 1.9700 - 3.5400
  • Volume 86,237,815
  • Avg. Volume 156,966,900
  • Market Cap (intraday) 17.664B
  • Beta (5Y Monthly) 0.51
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date --
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date Oct 15, 2024
  • 1y Target Est --

Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, ultra-high efficiency silicon wafers, and photovoltaic packaging materials and products, as well as photovoltaic glass and module products. In addition, it engages in the supply of oil and gas. The company was formerly known as SichuanHebang Biotechnology Co.,Ltd. and changed its name to Sichuan Hebang Biotechnology Corporation Limited in April 2021. The company was founded in 2002 and is based in Leshan, China.

www.hebang.cn

5,085

Full Time Employees

December 31

Fiscal Year Ends

Chemicals

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

603077.SS
11.50%
SSE Composite Index (000001.SS)
9.32%

1-Year Return

603077.SS
8.26%
SSE Composite Index (000001.SS)
9.73%

3-Year Return

603077.SS
15.48%
SSE Composite Index (000001.SS)
19.11%

5-Year Return

603077.SS
41.94%
SSE Composite Index (000001.SS)
1.46%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.04%

  • Return on Assets (ttm)

    0.58%

  • Return on Equity (ttm)

    -1.76%

  • Revenue (ttm)

    5.78B

  • Net Income Avi to Common (ttm)

    -175.63M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    7.48B

  • Total Debt/Equity (mrq)

    46.48%

  • Levered Free Cash Flow (ttm)

    -300.21M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: